ON-DEMAND WEBINAR
Blood-Based Biomarkers—How Metabolomics Assists Stroke Research to Improve Diagnosis and Monitoring
Like many neurological diseases, signs and symptoms of stroke vary widely in a given population. Both delayed diagnosis and ineffective treatment can have devastating consequences for victims of stroke and stroke-like diseases. Metabolomics provides an opportunity to tease apart this complex problem and moves the field toward precision medicine. Join Dr. Steffen Tiedt, M.D., Ph.D., Principal Investigator and Senior Physician at the Institute for Stroke and Dementia Research, Munich, as he guides us through his applications of metabolomics to stroke research. From identifying biomarkers of stroke for accurate diagnosis to applying a systems biology approach to examining the consequences of stroke, metabolomics, used in tandem with other omics, can derive actionable insights to improve both diagnosis and treatment for stroke patients.
During this webinar, you will learn:
- How metabolomics can be a powerful tool for studying biomarkers in stroke
- The benefits of outsourcing metabolomics experiments
- How metabolic signatures can be used to understand current disease state
- What types of follow-up questions can result from a metabolomics study
About Metabolomics
Metabolomics plays a critical role in understanding heterogeneous diseases like stroke by providing a snapshot of dynamic metabolic processes in biological systems. In neurological diseases like stroke, it can provide insight into the pathophysiology, making progress toward improved diagnosis which could lead to prevention. By analyzing the metabolome, scientists can discover novel biomarkers. On the other end of the disease process, metabolomic signatures, in combination with other omics, can improve understanding of disease progression and inform personalized treatment strategies to improve patient outcomes. Metabolomics offers a valuable tool to bridge the gap between molecular processes and clinical manifestations, paving the way for advancements in our ability to study, diagnose, and manage neurological diseases like stroke.
Dr. Steffen Tiedt, M.D., Ph.D.
Dr. Steffen Tiedt is a Principal Investigator and Senior Physician at the Institute for Stroke and Dementia Research, Munich, aiming to identify circulating signatures that inform on the local and systemic effects of stroke.
Dr. Tiedt studied medicine at Ludwig Maximilian University of Munich and Harvard University. Intrigued by courses on neurophysiology, he conducted his M.D. thesis with Dr. Magdalena Götz, exploring the role of STAT-signalling on the neurogenic potential of reactive astrocytes. In 2013, Dr. Tiedt joined the group of Martin Dichgans at the ISD as a clinician-scientist conducting a joint program: a Ph.D. in Neuroscience at the Graduate School of Systemic Neuroscience and residency in Clinical Neurology. During his Ph.D. work, he initiated the CIRCULAting biomarkers after Stroke (CIRCULAS) and PRecisiOn Medicine In StrokE (PROMISE) studies, which by now are among the largest studies world-wide with early and serial blood sampling in acute stroke patients (N > 2,000). Utilizing this resource, Dr. Tiedt and his team were the first to employ RNA sequencing for the identification of circulating miRNAs associated with stroke and to apply single-molecule array (Simoa™) technology during the course of stroke (publications in Circulation Research and Neurology).
Based on this work, Dr. Tiedt’s lab now utilizes profiling, ultrasensitive single-molecule, and point-of-care technologies to identify meaningful signatures to improve stroke care and explores underlying molecular and pathophysiological mechanisms in experimental settings.
